NCT01110642

Novel Treatment for Syndromic Ichthyoses

Open-label, Pilot Study to Assess Cholesterol-Lovastatin Solution in the Treatment of Syndromic Ichthyoses

• Status: Withdrawn
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: Northwestern University · Academic / Other
• Sex: All
• Age: 1 Year
• Healthy volunteers: Not accepted

Summary

This is an open label-pilot study to assess the efficacy and safety of a novel cholesterol-lovastatin topical solution in children with rare syndromic ichthyoses. Often times, these children have difficulty in finding easily applied treatments to make their psoriasiform and ichthyotic plaques more manageable. We propose the use of a cholesterol-lovastatin topical solution as a treatment option with the hypothesis that it will lead to regression of involved areas and decreased erythema and warty-like appearance of the plaques. We plan to enroll children with syndromic ichthyoses over the age of 1 year for a 12 month study with a total of 5 visits and 5 phone calls.

Conditions

• Syndromic Ichthyoses
• CHILD Syndrome
• Smith Lemli Opitz Syndrome
• Conradi Syndrome

Interventions

Type	Name	Description
DRUG	Lovastatin	Topical lovastatin applied to red, rashy areas two times daily for 12 months

Timeline

• Start date: 2011-07-01
• First posted: 2010-04-26
• Last updated: 2015-05-19